There are 594 resources available
LBA3 - Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
Presenter: Virginie Westeel
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Why we need yp-stages in future editions of the TNM classification?
Presenter: Hisao Asamura
Session: Treatment challenges in the light of the 9th edition TNM
Resources:
Slides
Webcast
Clinical case 2 - A case of oligometastatic small cell lung cancer
Presenter: Sevinc Balli
Session: YO Clinical cases discussion
Resources:
Slides
Webcast
188O - Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)
Presenter: Giulia Pasello
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Treatment challenges in the light of the 9th edition TNM
Resources:
Webcast
Expert discussion of clinical case 2
Presenter: Fiona McDonald
Session: YO Clinical cases discussion
Resources:
Webcast
Invited Discussant 187O, LBA3 and 188O
Presenter: Jonathan Spicer
Session: Proffered Paper session 2
Resources:
Slides
Webcast
Clinical case 3 - Challenges and pitfalls in the treatment of locally advanced RET-fusion positive NSCLC
Presenter: Rita Leporati
Session: YO Clinical cases discussion
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 2
Resources:
Webcast
Expert discussion of clinical case 3
Presenter: JORDI REMON MASIP
Session: YO Clinical cases discussion
Resources:
Slides
Webcast